Literature DB >> 28220935

Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study.

Anthony R Mato1, Colleen Timlin1, Chaitra Ujjani2, Alan Skarbnik3, Christina Howlett3, Rahul Banerjee1, Chadi Nabhan4, Stephen J Schuster1.   

Abstract

Entities:  

Keywords:  Bruton's tyrosine kinase; Ibrutinib; chronic lymphocytic leukaemia

Mesh：

Substances：

Year:  2017        PMID： 28220935     DOI： 10.1111/bjh.14540

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  20 in total

Review 1.  Real-World Evidence for Chronic Lymphocytic Leukemia in the Era of Targeted Therapies.

Authors:  Prioty Islam; Anthony R Mato
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

2.  Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience.

Authors:  AnnaLynn M Williams; Andrea M Baran; Carla Casulo; Patrick Reagan; Jonathan W Friedberg; Margaret Helber; Jeremiah Moore; Elizabeth Baloga; Clive S Zent; Paul M Barr
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-10-13

3.  Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL.

Authors:  Inhye E Ahn; Neil Basumallik; Xin Tian; Susan Soto; Adrian Wiestner
Journal:  Blood       Date:  2019-03-27       Impact factor: 22.113

4.  Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort.

Authors:  Maria Winqvist; Per-Ola Andersson; Anna Asklid; Karin Karlsson; Claes Karlsson; Birgitta Lauri; Jeanette Lundin; Mattias Mattsson; Stefan Norin; Anna Sandstedt; Richard Rosenquist; Florentin Späth; Lotta Hansson; Anders Österborg
Journal:  Haematologica       Date:  2018-12-04       Impact factor: 9.941

5.  Overcoming resistance to targeted therapies in chronic lymphocytic leukemia.

Authors:  Sigrid S Skånland; Anthony R Mato
Journal:  Blood Adv       Date:  2021-01-12

6.  Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.

Authors:  K Uminski; K Brown; O Bucher; I Hibbert; D H Dhaliwal; J B Johnston; M Geirnaert; D E Dawe; V Banerji
Journal:  Curr Oncol       Date:  2019-10-01       Impact factor: 3.677

7.  Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia.

Authors:  Paul J Hampel; Timothy G Call; Kari G Rabe; Wei Ding; Eli Muchtar; Saad S Kenderian; Yucai Wang; Jose F Leis; Thomas E Witzig; Amber B Koehler; Amie L Fonder; Susan M Schwager; Daniel L Van Dyke; Esteban Braggio; Susan L Slager; Neil E Kay; Sameer A Parikh
Journal:  Oncologist       Date:  2020-09-20

8.  Reduced Dose Ibrutinib Due to Financial Toxicity in CLL.

Authors:  Deepesh P Lad; Pankaj Malhotra; Alka Khadwal; Gaurav Prakash; Arihant Jain; Subhash Varma
Journal:  Indian J Hematol Blood Transfus       Date:  2018-09-08       Impact factor: 0.900

9.  Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.

Authors:  Lindsey E Roeker; Christopher P Fox; Toby A Eyre; Danielle M Brander; John N Allan; Stephen J Schuster; Chadi Nabhan; Brian T Hill; Nirav N Shah; Frederick Lansigan; Maryam Yazdy; Bruce D Cheson; Nicole Lamanna; Arun K Singavi; Catherine C Coombs; Paul M Barr; Alan P Skarbnik; Mazyar Shadman; Chaitra S Ujjani; Hande H Tuncer; Allison M Winter; Joanna Rhodes; Colleen Dorsey; Hannah Morse; Charlene Kabel; John M Pagel; Annalynn M Williams; Ryan Jacobs; Andre Goy; Sivraj Muralikrishnan; Laurie Pearson; Andrea Sitlinger; Neil Bailey; Anna Schuh; Amy A Kirkwood; Anthony R Mato
Journal:  Clin Cancer Res       Date:  2019-04-19       Impact factor: 12.531

Review 10.  How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.

Authors:  Deborah M Stephens; John C Byrd
Journal:  Blood       Date:  2019-01-14       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.